The number of potential antimicrobial therapies developed by the world's biggest drugmakers has increased by 35% over the past five years, according to a new analysis. The analysis focuses on major drug manufacturers. These manufacturers are developing fewer antibiotics. The study evaluates the development of antimicrobial therapies. The findings show a 35% increase in the number of potential therapies. Despite this, the development of antibiotics specifically by large companies is declining. The analysis highlights trends in the pharmaceutical sector.